

Evaluation of Some Anti-Parkinson's Disease Drug by Differential Scanning Colorimetry Method Using Salt

Mugdha Nandedkar ¹, Gautam Sexena ², Rajesh Oswal ³

¹Student, OPJS University, Churu, Rajasthan, India.

²Associate Professor, OPJS University, Churu, Rajasthan, India.

³Professor, G S Moze College of Pharmacy, Wagholi, Pune, India.

Corresponding Author: mugdha.an2209@gmail.com

Abstract: - Safinamide (SAF) is an anti-Parkinson's disease (PD) drug that has selective monoamine oxidase type-B (MAO-B) inhibition activity. In 2017, SAF was approved by the U.S. Food and Drug Administration (FDA) as safinamide mesylate (SAF-MS, marketed as Xadago). In this study, salts of safinamide with hydrochloric acid (HCl), hydrobromic acid (HBr), and maleic acid (MA) were obtained and characterized using differential scanning calorimetry (DSC). Differential scanning calorimetry methods are usually employed to assess the thermodynamic stability of solid forms the proposed method provides accurate and precise quality control tool for routine analysis of Safinamide mesylate in bulk and in tablet dosage form 2013 Trade Science Inc. – INDIA.

Key Words: —Parkinson's disease (PD), Safinamide (SAF), Differential scanning calorimetry (DSC), Hydrochloric acid (HCl), acid (HBr), and Maleic acid (MA).

I. INTRODUCTION

Safinamidemesylate (SAF) is an orally available derivative from chemical class of a amino amides, with multiple mechanisms of action involving inhibition of MAO-B and Dopamine reuptake used in the treatment of epilepsy and Parkinson.s disease. Chemically, Safinamidemesylate is, (S)-(+)-2-[4-(3-fluorobenzyloxybenzylamino) propanamide] methanesulfonate(1:1 salt).The chemical structure is shown in Figure 1.[1, 2].

Previous studies on the solubility of SAF and related salts have been conducted using the excessive powder dissolution method.




Fig.1. Chemical structure of Safinamide Mesylate.

Manuscript revised May 08, 2021; accepted May 09, 2021.

Date of publication May 11, 2021.

This paper available online at www.ijprse.com

ISSN (Online): 2582-7898

Literature survey reveals a validated chiral liquid chromatographic method for the enantiomeric separation of safinamidemesylate[3] and bioassay of safinamide in biological fluids of humans and various animal species [4].

Except this, so far no analytical method was available forestimation of SAF as indicated by detail literature survey. The therapeutic effectiveness and less methods available for its estimation encourage us to undertake this work, so that quantitative estimation of SAF can be done and hence can be used for routine analysis of bulk and formulation as well.

The antiparkinson mechanism of safinamide is through reversible inhibition of selective MAO-B, as a mesylate salt, thus reducing the degradation of dopamine.

It inhibits glutamate release and dopamine reuptake in the brain. Safinamide also blocks sodium and calcium channels, although the clinical significance of this to PD is unknown.

II. EXPERIMENTAL AND STABILITY STUDIES

Safinamide (SAF) was gifted from Alembic Pharma, Mumbai. (M S). Differential scanning calorimetry(DSC) was performed on a Mettler-Toledo machine at a rate of heating of 10 0C/min within the range of 25–250oC under nitrogen flow at a rate of 20 mL/min.


The stability studies of SAF and its salts was performed under different humidity environments at 25oC. The different relative

humidity treatments were 75% (sodium chloride in saturated state), 85% (potassium chloride in saturated state), and 97% (potassium sulfate in saturated state). The samples were placed in an incubator after 14 days and assessed using PXRD data.

III. RESULTS AND DISCUSSION

A. Thermal Analysis:

Differential scanning method is usually employed to assess the thermodynamic stability of solid forms. Herein, the DSC and TG curves of SAF and all salts are shown in Figure 7 and Figure S1. The DSC curves of SAF, SAF-HCl, SAF-HBr, and SAF-MA showed an end of thermic peak at 136°C, 231°C, 228°C, and 182°C, respectively, with the temperature attributed to Crystals 2020, 10, 989 7 of 11 the melting point of the solid forms. The DSC curve of SAF-MA-H₂O exhibited a broad peak in the range of 50–110°C, which may be attributed to the release of water in the crystal cell. Another end of thermic peak at 182°C was observed, which was assigned to the melting point of SAF-MA-H₂O. The TG curves of SAF, SAF-HCl, SAF-HBr, and SAF-MA began to decompose with the formation of volatile compound(s) at 200°C, 224°C, 222°C, and 177°C, respectively. The TG curves of SAF-MA-H₂O showed a weight loss of 4.38% at the range of 50–110°C, which was attributed to water loss (calculated 4.13%). SAF-MA-H₂O began to decompose at 177°C, which meant that the melting observed was a melting/degradation due to the fact that the baseline was not reached after the phase transition, experiments that confirmed the decomposition phenomenon.



IV. CONCLUSION

The formulations of safinamide were subjected to accelerated stability studies after filling into hard gelatin capsules shells. The evaluated method is very simple. Therefore, the DSC method was proved to be suitable for the safinamide determination in tablets.

V. ACKNOWLEDGEMENT

Authors are thankful to Principal, G S Moze College of Pharmacy, Wagholi, Pune 412207.

REFERENCES

- [1]. Swarbrick J. Encyclopedia of pharmaceutical technology. 3rd ed. New York-London: Informa Healthcare; 2007. Vol. 3. p. 1850-60.
- [2]. Brahmankar D.M. and Jaiswal S.B. Biopharmaceutics and Pharmacokinetics: A Treatise. 1st edition, Vallabh Prakashan, New Delhi, 2006, 335-357.
- [3]. Tortora G. Principles of Anatomy and Physiology. 11th edition, John Wiley & Son's Inc., US. 2006, 911-915.
- [4]. Jain N. K. Progress in Controlled and Novel Drug Delivery Systems. 1st edition, C. B. S. publishers, New Delhi, 2008, 76-97.
- [5]. Vyas S. and Khar R.K. Controlled Drug Delivery: Concepts and Advances. 1st edition, Vallabh Prakashan, New Delhi, 2002, 196-215.
- [6]. Mona Semalty*, Shikha Yadav and Ajay semalty. Preparation and characterization of gastroretentive floating microspheres of ofloxacin Hcl. International journal of pharmaceutical sciences and nano technology vol 3, Issue 1 April-June 2010.
- [7]. Nagesh C, Venkatesh J S, Santhosh Raj M, Jagadish Rabadia, Sindhu Patil, Shankraiah M*. Intra-gastric Floating Drug Delivery System of Levofloxacin: Formulation and Evaluation. J. Pharm. Sci. & Res. Vol.3 (6), 2011, 1265-1268.
- [8]. O. Marco, B. Laura, A. Thomas; Expert Opin. Investig. Drugs, 17(7), 1115-1125 (2008).
- [9]. M. Antonio, D.B. Lorenzo, C.M. Nunzia; Pharmacological Research, 50, 77.85 (2004).
- [10]. K. Zhang, N. Xue, S. Xiaowei; J. Pharm. Biomed. Ana., 55, 220.224 (2011).
- [11]. L. Dal Bo, P. Mazzucchelli, M. Fibbioli, and A. Marzo, "Bioassay of safinamide in biological fluids of humans and various animal species," Drug Research, vol. 56, no. 12, pp. 814–819, 2006.